Dr. Mayilvahanan Bose

Dr. Mayilvahanan Bose

Associate Professor, Department of Molecular Oncology

Colon CancerOvarian & Women's CancersGastric Cancer
Biomarker DiscoveryTranslational DiagnosticsMicrobiome & Metagenomics
View on PubMed

Our goal is to bridge the gap between laboratory discoveries and affordable cancer diagnostics — making early detection accessible to every patient, regardless of where they live.

Research

The Problem

Cervical cancer remains the second most common cancer among Indian women, while colorectal cancer incidence is rising rapidly — particularly early-onset CRC in younger populations. Current screening tools are often expensive, require specialized infrastructure, and are inaccessible to the majority of India's population. The gut microbiome's role in cancer development is poorly understood in Indian populations, where dietary patterns, genetics, and microbial exposures differ significantly from Western cohorts.

The Approach

Dr. Bose's laboratory employs a multi-pronged translational research strategy: developing affordable biomarker-based screening tools (DAS-ELISA for HPV/p16 detection), characterizing the colorectal cancer-associated gut microbiome using 16S rRNA gene sequencing and whole metagenome analysis, and building international research networks to compare microbial patterns across populations. The lab collaborates with institutions in the UK, Chile, Argentina, and Vietnam through GCRF-funded networks, and coordinates a 12-center pan-India consortium (PEACOCC) to study early-onset CRC. Machine learning models are being applied to microbiome data for predictive diagnostics.

Innovations & Discoveries

The p16 DAS-ELISA technology for cervical cancer screening was successfully developed and transferred to HLL Lifecare Limited — a Government of India Enterprise — for large-scale manufacturing and deployment. Gut microbiome profiling has revealed that India-specific CRC microbiome signatures show geographic distinctness but share universal CRC-associated patterns with UK cohorts. A notable finding from the international E. coli (pks+) study showed 4% prevalence in Indian CRC patients compared to 31% in the UK NHSBCSP cohort, suggesting distinct genotoxic mechanisms. The PEACOCC consortium is generating the first comprehensive characterization of early-onset CRC microbial composition across India.

Research Interests

Biomarker DiscoveryTranslational DiagnosticsMicrobiome & MetagenomicsAntimicrobial Resistance

Research Projects

Large bowel microbiome — a network approach to unravelling the relationship between gut microbiota and colorectal cancer in India and the UK

Completed

Funding: Global Challenges Research Fund (GCRF), UK

Role: Co-PI

OPTIMISTICC Grand Challenge

Ongoing

Funding: Cancer Research UK

Role: PI (India Site)

ID-PPP-OTN: Infectious Diseases — Public Private Partnerships on Treatment and Novel diagnostics

Completed

Funding: SERB, Department of Science and Technology

Role: Co-PI

PEACOCC: Pan-India Early-onset CRC Microbial Composition Characterization

Ongoing

Funding: DBT/Wellcome Trust India Alliance

Role: Site-PI

MolOnco-DnT-CenTr: Molecular Oncology Diagnostics & Therapeutics Centre

Ongoing

Funding: ICMR-CAR

Role: Site-PI

Awards & Achievements

  • Young Immunologists from the Developing World Award — International Union of Immunological Societies (IUIS)
  • Technology Transfer: p16 DAS-ELISA to HLL Lifecare Limited, Government of India Enterprise
  • DHR-ICMR International Fellow (2025–2026)

Our Team

Selected Publications

Gut microbiome in Indian and UK colorectal cancer shows geographic differences but universal CRC-associated patterns

Thomas J, Ohlsson L, Sena M, Kumar V, Nair S, Kalarani D, Aishwarya P, Singarayer de Sylva A, Priya VM, Bose M, Quirke P, Hasan S, Sejnova D, Vymetalkova V, Vodickova L, Brennan P, Vodicka P, Sillo T, and Cross A

npj Biofilms and Microbiomes11: 9(2025)DOI

An international study of E.coli (pks+) prevalence in patients with colorectal cancer and healthy population controls

Ohlsson L, Thomas J, Shinde V, Bose M, Sena M, Jain V, Fonseca F, Miquel S, and Cross A

Scientific Reports14: 29741(2024)DOI

Profiling Antibiotic Resistance in Colorectal Cancer Samples using Whole Metagenome Sequencing

Sena M, Kumar V, Bose M, Kalarani I, Yoosuf S, Aishwarya P, Priya VM, Akshaya, Nair S, Ohlsson L, Brennan P, Thomas J, and Cross A

BMC Microbiology24: 441(2024)DOI

Investigating the gut microbiome of subjects with early-onset colorectal cancer from India

Bose M, Sena M, Kumar V, Kalarani I, Yoosuf S, Priya VM, Aishwarya P, Akshaya, Nair S, Ohlsson L, Cross A, and Thomas J

Microbiology Spectrum (ASM)(2024)DOI

Overview of Cervical Cancer Screening and Triage - A South Indian perspective

Jayalakshmi K, Bose M, Vanitha NS, Lavanya M, Priya VM, Baskar K, Krishna Priya S, Nair S, and Thomas J

Journal of Clinical Gynecology and Obstetrics13: 21-30(2024)DOI

Join Our Lab

We are looking for motivated researchers to join our team.

Eligibility: Prospective PhD candidates with own fellowship (Inspire / DBT JRF / ICMR-JRF / CSIR-NET)

View Open Positions

Contact

Department of Molecular Oncology

Cancer Institute (WIA), Adyar, Chennai — 600 036

b.mayilvahanan@cancerinstitutewia.org